EP-1137 DW MRI as biomarker of response during RT for intermed/high risk SCC oropharynx: a feasibility study

C. Paterson, I. McCrea, L. Hay, S. Allwood-Speirs, L. Devlin, M. Sankaralingam, P. McLoone, C. Wilson, D. Grose, A. James, C. Lamb, M. Rizwanullah, S. Schipani, Ioanna Nixon, M. Thomson, M. McJury, J. Foster, A. Duffton

Research output: Contribution to journalMeeting abstractpeer-review

1 Downloads (Pure)


Despite radical chemo-radiotherapy (CRT), many patients with intermediate and high risk SCC oropharynx (OPSCC) relapse. Treatment related toxicity limits further uniform intensification across the patient group. If a predictive biomarker for outcomes from CRT can be identified during treatment, individualised and adaptive treatment strategies may be employed for the non-responders. This is the 1st study to use DW MRI for early response assessment in a specific H&N sub-site with sub-type of similar biological behaviour.
Original languageEnglish
Pages (from-to)S631-S632
Number of pages2
JournalRadiotherapy and Oncology
Publication statusPublished - 30 Apr 2019
EventThe European Society for Radiotherapy and Oncology Conference 38 - Milan, Italy
Duration: 26 Apr 201830 Apr 2019


  • EP-1137
  • DW MRI
  • biomarker
  • response
  • RT
  • intermed/high risk SCC oropharynx
  • feasibility study

Cite this